vs
Side-by-side financial comparison of Andersons, Inc. (ANDE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Andersons, Inc. is the larger business by last-quarter revenue ($329.5M vs $196.9M, roughly 1.7× Pacira BioSciences, Inc.). On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.1% vs -2.4%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $-77.1M). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (8.5% CAGR vs -1.8%).
The Andersons, Inc. is an American agribusiness established in 1947, that began as Andersons Truck Terminal (ATT) in the 1940s for the grain industry, headquartered in Maumee, Ohio. It is a diversified company rooted in agriculture that conducts business in the commodity merchandising, renewables, and plant nutrient sectors.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ANDE vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $329.5M | $196.9M |
| Net Profit | $67.4M | — |
| Gross Margin | 70.3% | 79.5% |
| Operating Margin | 26.6% | 1.2% |
| Net Margin | 20.5% | — |
| Revenue YoY | -2.4% | 5.1% |
| Net Profit YoY | 49.6% | — |
| EPS (diluted) | — | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $329.5M | $196.9M | ||
| Q3 25 | $295.8M | $179.5M | ||
| Q2 25 | $535.0M | $181.1M | ||
| Q1 25 | $370.8M | $168.9M | ||
| Q4 24 | $337.5M | $187.3M | ||
| Q3 24 | $231.9M | $168.6M | ||
| Q2 24 | $492.5M | $178.0M | ||
| Q1 24 | $341.4M | $167.1M |
| Q4 25 | $67.4M | — | ||
| Q3 25 | $20.1M | $5.4M | ||
| Q2 25 | $7.9M | $-4.8M | ||
| Q1 25 | $284.0K | $4.8M | ||
| Q4 24 | $45.1M | — | ||
| Q3 24 | $27.4M | $-143.5M | ||
| Q2 24 | $36.0M | $18.9M | ||
| Q1 24 | $5.6M | $9.0M |
| Q4 25 | 70.3% | 79.5% | ||
| Q3 25 | 57.8% | 80.9% | ||
| Q2 25 | 29.6% | 77.4% | ||
| Q1 25 | 41.2% | 79.7% | ||
| Q4 24 | 63.1% | 78.7% | ||
| Q3 24 | 76.4% | 76.9% | ||
| Q2 24 | 35.6% | 75.1% | ||
| Q1 24 | 37.6% | 71.6% |
| Q4 25 | 26.6% | 1.2% | ||
| Q3 25 | 8.7% | 3.5% | ||
| Q2 25 | 4.6% | 4.7% | ||
| Q1 25 | 0.9% | 1.2% | ||
| Q4 24 | 19.9% | 13.2% | ||
| Q3 24 | 26.8% | -82.8% | ||
| Q2 24 | 11.6% | 15.9% | ||
| Q1 24 | 4.1% | 7.9% |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 6.8% | 3.0% | ||
| Q2 25 | 1.5% | -2.7% | ||
| Q1 25 | 0.1% | 2.8% | ||
| Q4 24 | 13.4% | — | ||
| Q3 24 | 11.8% | -85.1% | ||
| Q2 24 | 7.3% | 10.6% | ||
| Q1 24 | 1.6% | 5.4% |
| Q4 25 | — | $0.05 | ||
| Q3 25 | $0.59 | $0.12 | ||
| Q2 25 | $0.23 | $-0.11 | ||
| Q1 25 | $0.01 | $0.10 | ||
| Q4 24 | $1.31 | $0.38 | ||
| Q3 24 | $0.80 | $-3.11 | ||
| Q2 24 | $1.05 | $0.39 | ||
| Q1 24 | $0.16 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.3M | $238.4M |
| Total DebtLower is stronger | $560.0M | $372.2M |
| Stockholders' EquityBook value | $1.2B | $693.1M |
| Total Assets | $3.7B | $1.3B |
| Debt / EquityLower = less leverage | 0.45× | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $98.3M | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | $561.8M | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M | ||
| Q1 24 | — | $325.9M |
| Q4 25 | $560.0M | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | $608.2M | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $693.1M | ||
| Q3 25 | $1.2B | $727.2M | ||
| Q2 25 | $1.4B | $757.8M | ||
| Q1 25 | $1.4B | $798.5M | ||
| Q4 24 | $1.4B | $778.3M | ||
| Q3 24 | $1.3B | $749.6M | ||
| Q2 24 | $1.3B | $879.3M | ||
| Q1 24 | $1.3B | $892.2M |
| Q4 25 | $3.7B | $1.3B | ||
| Q3 25 | $3.3B | $1.3B | ||
| Q2 25 | $3.4B | $1.5B | ||
| Q1 25 | $3.8B | $1.6B | ||
| Q4 24 | $4.1B | $1.6B | ||
| Q3 24 | $3.4B | $1.5B | ||
| Q2 24 | $3.3B | $1.6B | ||
| Q1 24 | $3.3B | $1.6B |
| Q4 25 | 0.45× | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | 0.45× | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.2M | $43.7M |
| Free Cash FlowOCF − Capex | $-77.1M | $43.5M |
| FCF MarginFCF / Revenue | -23.4% | 22.1% |
| Capex IntensityCapex / Revenue | 21.5% | 0.1% |
| Cash ConversionOCF / Net Profit | -0.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-56.1M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.2M | $43.7M | ||
| Q3 25 | $233.9M | $60.8M | ||
| Q2 25 | $299.3M | $12.0M | ||
| Q1 25 | $-350.0M | $35.5M | ||
| Q4 24 | $268.8M | $33.1M | ||
| Q3 24 | $-2.1M | $53.9M | ||
| Q2 24 | $304.4M | $53.2M | ||
| Q1 24 | $-239.6M | $49.1M |
| Q4 25 | $-77.1M | $43.5M | ||
| Q3 25 | $167.0M | $57.0M | ||
| Q2 25 | $250.5M | $9.3M | ||
| Q1 25 | $-396.6M | $26.9M | ||
| Q4 24 | $212.9M | $31.0M | ||
| Q3 24 | $-40.0M | $49.8M | ||
| Q2 24 | $275.8M | $51.6M | ||
| Q1 24 | $-266.4M | $46.3M |
| Q4 25 | -23.4% | 22.1% | ||
| Q3 25 | 56.5% | 31.7% | ||
| Q2 25 | 46.8% | 5.1% | ||
| Q1 25 | -106.9% | 15.9% | ||
| Q4 24 | 63.1% | 16.6% | ||
| Q3 24 | -17.2% | 29.6% | ||
| Q2 24 | 56.0% | 29.0% | ||
| Q1 24 | -78.0% | 27.7% |
| Q4 25 | 21.5% | 0.1% | ||
| Q3 25 | 22.6% | 2.2% | ||
| Q2 25 | 9.1% | 1.5% | ||
| Q1 25 | 12.6% | 5.1% | ||
| Q4 24 | 16.6% | 1.1% | ||
| Q3 24 | 16.3% | 2.4% | ||
| Q2 24 | 5.8% | 0.9% | ||
| Q1 24 | 7.8% | 1.7% |
| Q4 25 | -0.09× | — | ||
| Q3 25 | 11.61× | 11.20× | ||
| Q2 25 | 38.10× | — | ||
| Q1 25 | -1232.46× | 7.37× | ||
| Q4 24 | 5.96× | — | ||
| Q3 24 | -0.08× | — | ||
| Q2 24 | 8.46× | 2.82× | ||
| Q1 24 | -42.94× | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANDE
| Specialty And Primary Nutrients | $137.1M | 42% |
| Premium Ingredients | $66.1M | 20% |
| Segment Reporting Reconciling Item Other | $63.2M | 19% |
| Other | $63.1M | 19% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
